Earnings Call Summary | Trinity Biotech(TRIB.US) Q1 2024 Earnings Conference
Earnings Call Summary | Trinity Biotech(TRIB.US) Q1 2024 Earnings Conference
The following is a summary of the Trinity Biotech Plc (TRIB) Q1 2024 Earnings Call Transcript:
以下是三一生物技术有限公司(TRIB)2024年第一季度财报电话会议记录的摘要:
Financial Performance:
财务业绩:
Trinity Biotech saw nearly 40% quarter-on-quarter growth in Point-of-Care revenues largely attributed to the success of the TrinScreen HIV screening test.
Q1 2024 revenues amounted to $14.7 million, a slight decrease from Q1 2023 due to the loss of transplant testing activity at the Buffalo lab.
The gross margin improved to 37.6% in light of cost-saving initiatives and is expected to increase with the scaling of production.
Opex reduced with an operating loss of $3 million, an improvement from the Q1 2023 loss of $3.9 million.
Trinity Biotech的即时医疗收入同比增长了近40%,这在很大程度上归因于TrinScreen艾滋病毒筛查测试的成功。
由于布法罗实验室的移植测试活动中断,2024年第一季度收入为1,470万美元,较2023年第一季度略有下降。
由于采取了节省成本的举措,毛利率提高至37.6%,预计将随着生产规模的扩大而增加。
运营支出减少了300万美元,比2023年第一季度的390万美元亏损有所改善。
Business Progress:
业务进展:
Trinity Biotech has been executing key strategic initiatives, such as acquiring new glucose monitoring technology with a view to growth in 2024 and 2025.
It applied for ethical approval to initiate a pre-pivotal clinical trial and plans on entering pivotal clinical trials by summer 2025, with EU regulatory approval scheduled for the end of that year.
The company signed a strategic collaboration with software companies like PulseAI, launched a new CGM microsite, and appointed Avinash Kale as the director for the CGM program.
Trinity Biotech is also making moves to negotiate better pricing from suppliers for raw materials.
Trinity Biotech一直在执行关键战略举措,例如收购新的血糖监测技术,以期在2024年和2025年实现增长。
它申请伦理批准,启动一项关键前临床试验,并计划在2025年夏季之前进入关键临床试验,欧盟监管部门的批准定于当年年底进行。
该公司与PulseAI等软件公司签署了战略合作协议,推出了新的CGM微型网站,并任命Avinash Kale为CGM计划的董事。
Trinity Biotech也在采取行动,与供应商谈判更优惠的原材料价格。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。